Jingyu Li; Yu Zhao; Yan Zheng; Xuexia Zhang; Ya Jiang; Jiangshu Guo; Wenmei Bao; Yinfeng Ma; Yaoyuan Zhang; Shuyuan Yin; Yirui Ma; Lijie Wang; Xiaoqiang Liu; Jingyu Li; Yu Zhao; Yan Zheng; Xuexia Zhang; Ya Jiang; Jiangshu Guo; Wenmei Bao; Yinfeng Ma; Yaoyuan Zhang; Shuyuan Yin; Yirui Ma; Lijie Wang; Xiaoqiang Liu

doi:10.46234/ccdcw2026.083

[1]

World Health Organization. Rabies vaccines: WHO position paper, April 2018 - Recommendations. Vaccine 2018;36(37):5500 − 3. https://doi.org/10.1016/j.vaccine.2018.06.061.

[2]

Yang CX, Dang M, Wu LJ, Jin GL, Deng QQ, Chen YH, et al. Disparities in Global Rabies Burden from GBD 2021: children, older adults, and low-SDI countries at continued risk. PLoS Negl Trop Dis 2025;19(10):e0013630. https://doi.org/10.1371/journal.pntd.0013630.

[3]

World Health Organization. Rabies. 2024. Available online: https://www.who.int/news-room/fact-sheets/detail/rabies (accessed on 21 April 2026).

[4]

World Health Organization. WHO expert consultation on rabies. Second report. Geneva: WHO; 2013. https://www.who.int/publications/i/item/WHO-TRS-982.

[5]

Zhou H, Li Y, Chen RF, Tao XY, Yu PC, Cao SC, et al. Technical guideline for human rabies prevention and control (2016). Chin J Epidemiol 2016;37(2):139 − 63. https://doi.org/10.3760/cma.j.issn.0254-6450.2016.02.001.

[6]

National Medical Products Administration. Guidelines for grading criteria for adverse events in clinical trials of prophylactic vaccines. Beijing: NMPA; 2019. Available from: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191231111901460.html. (In Chinese).

[7]

Barber J, Al-Majdoub ZM, Couto N, Howard M, Elmorsi Y, Scotcher D, et al. Toward systems-informed models for biologics disposition: covariates of the abundance of the neonatal Fc Receptor (FcRn) in human tissues and implications for pharmacokinetic modelling. Eur J Pharm Sci 2023;182:106375. https://doi.org/10.1016/j.ejps.2023.106375.

[8]

Hardiansyah D, Ng CM. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling. mAbs 2018;10(7):1144 − 56. https://doi.org/10.1080/19420862.2018.1494479.

[9]

Temrikar ZH, Suryawanshi S, Meibohm B. Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients. Pediatr Drugs 2020;22(2):199 − 216. https://doi.org/10.1007/s40272-020-00382-7.

[10]

Liu XQ, Li YF, Li JY, Zhou JM, Guo JS, Pu Y, et al. Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: a phase III, randomized, double-blind, non-inferiority trial. Int J Infect Dis 2023;134:53 − 62. https://doi.org/10.1016/j.ijid.2023.05.017.